<DOC>
	<DOCNO>NCT00981175</DOCNO>
	<brief_summary>The purpose study assess safety , tolerability , immunogenicity , duration immunity one two dose ChimeriVax™-JE vaccine separate 5 6 month adult . Objectives : Safety : - Obtain safety tolerability data single , fix dose ChimeriVax™-JE compare placebo adult volunteer ( ≥ 18 &lt; 55 year ) without prior Japanese encephalitis ( JE ) vaccination . Immunogenicity : - Obtain data antibody response adult volunteer follow administration ChimeriVax™-JE - Assess durability immune response adult volunteer 60 month follow one two dose ChimeriVax™-JE .</brief_summary>
	<brief_title>A Study ChimeriVax™-JE Live Attenuated Vaccine Healthy Adults</brief_title>
	<detailed_description>Participants receive ChimeriVax™-JE diluent Day 0 diluent ChimeriVax™-JE Day 28 . A subset participant group receive booster dose ChimeriVax™-JE Month 6 . Follow-up visit occur 12 24 month . Eligible participant enter long-term immunogenicity follow-up period visit approximately 36 , 48 , 60 month Day 0 . No safety data collect long-term immunogenicity follow-up period .</detailed_description>
	<mesh_term>Encephalitis</mesh_term>
	<mesh_term>Encephalitis , Japanese</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>Inclusion Criteria : At entry : All aspect protocol explain write informed consent obtain subject . Aged ≥ 18 &lt; 55 year . In good general health , without significant medical history , physical examination finding , clinically significant abnormal laboratory result . Subject must available study duration , include plan followup visit . Has subject agree take follow precaution avoid insect bite 7 day follow vaccination : ( ) wear longsleeved shirt trouser ? ; ( b ) apply N , NDiethylmetatoluamide ( DEET ) contain insect repellent ? ; ( c ) Sleep screen enclosure ? For female subject childbearing potential : Negative serum pregnancy test . An efficacious hormonal ( i.e. , oral , implantable injectable ) barrier method birth control must use least 1 month Screening Month 6 least 1 month Day 28 Month 6 . These subject sign agreement birth control practise specify period specify method use . Female subject unable bear child must document ( e.g. , tubal ligation hysterectomy ) . For longterm immunogenicity followup period : Subject receive initial dose ChimeriVax™JE , baseline ( Day 0 ) sample least one postvaccination evaluable serological specimen antibody analysis . All aspect Longterm Immunogenicity Followup Period explain updated write informed consent obtain subject . In good general health , without significant medical history may affect efficacy endpoint ability take blood sample . Exclusion Criteria : A history vaccination Japanese encephalitis ( JE ) . Previous vaccination determine history ( interview subject ) and/or review subject 's vaccination card official documentation ( either history documentation vaccination fulfil criterion exclusion ) . Known suspected immunodeficiency ( e.g. , human immunodeficiency virus [ HIV ] infection , primary immunodeficiency disorder , leukemia , lymphoma ) , use immunosuppressive antineoplastic drug ( corticosteroid &gt; 10 mg prednisone , equivalent , 14 day last three month ) . Clinically significant abnormality laboratory assessment . Serious adverse reaction characterise urticaria angioedema prior vaccine . Transfusion blood treatment blood product , include intramuscular intravenous serum globulin within six month Screening Visit Day 56 . Administration another vaccine within 30 day precede screening visit Day 56 ( subject reschedule vaccination later date ) . Physical examination indicate clinically significant medical condition . Body temperature &gt; 38.1°C ( 100.6°F ) acute illness within 3 day prior inoculation ( subject may reschedule ) . Intention travel area prior study visit Day 56 . Seropositive hepatitis C virus ( HCV ) HIV positive hepatitis B ( HBV ) ( antigen ) . Lactation intend pregnancy female subject . Excessive alcohol consumption , drug abuse , significant psychiatric illness . A know suspected physiological structural condition compromise integrity bloodbrain barrier ( e.g. , significant hypertensive cerebrovascular disease , trauma , ischemia , infection , inflammation brain ) . For longterm immunogenicity followup period : History Yellow Fever study JE vaccination know flavivirus infection since receive ChimeriVax™JE vaccination Day 0 Day 28 ( doubleblind treatment period study ) . Yellow Fever/JE vaccination flavivirus infection determine history ( interview subject ) and/or review subject 's medical record . Please note subject flavivirus positive Day 0 allow enrol study . Participation another JE clinical study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>54 Years</maximum_age>
	<verification_date>July 2012</verification_date>
	<keyword>Japanese Encephalitis</keyword>
	<keyword>Japanese Encephalitis Vaccines</keyword>
	<keyword>Adult</keyword>
</DOC>